Free Trial
LON:RENE

ReNeuron Group (RENE) Share Price, News & Analysis

ReNeuron Group logo
GBX 3.38 -0.08 (-2.17%)
(As of 02/5/2024)

About ReNeuron Group Stock (LON:RENE)

Key Stats

Today's Range
3.28
3.50
50-Day Range
3.38
3.38
52-Week Range
3.28
11.50
Volume
177,373 shs
Average Volume
578,249 shs
Market Capitalization
£1.93 million
P/E Ratio
N/A
Dividend Yield
0.76%
Price Target
N/A
Consensus Rating
N/A

Company Overview

ReNeuron Group plc researches, develops, and commercializes cell-based therapies in the United Kingdom. The company engages in the development of CTX stem cell therapy candidate for treating stroke disability; and human retinal progenitor cell therapy that is in Phase 2 clinical trial for treating retinitis pigmentosa, a blindness-causing disease. It also develops CTX-derived exosomes that are in the pre-clinical stage, which are Nano-sized vesicles secreted by stem cells. In addition, the company licenses ReNcell products. It has a collaboration agreement with University College London to conduct research into the generation of immune cells from induced pluripotent stem cells for anti-cancer cell therapies. The company was founded in 1997 and is headquartered in Pencoed, the United Kingdom.

Receive RENE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ReNeuron Group and its competitors with MarketBeat's FREE daily newsletter.

RENE Stock News Headlines

Central Bank Abandons USD
You know what doesn't care about elections? Gold. If you want to protect your savings & retirement from our exploding national debt, VOTE FOR GOLD!
See More Headlines

RENE Stock Analysis - Frequently Asked Questions

ReNeuron Group's stock was trading at GBX 3.50 at the start of the year. Since then, RENE stock has decreased by 3.6% and is now trading at GBX 3.38.
View the best growth stocks for 2024 here
.

ReNeuron Group plc (LON:RENE) issued its quarterly earnings results on Monday, July, 20th. The company reported ($35.90) earnings per share for the quarter, topping the consensus estimate of ($50.20) by $14.30.

Shares of RENE stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that ReNeuron Group investors own include 10094 (IRD.TO) (IRD), Sareum (SAR), ValiRx (VAL), IOG (IOG), Dignity (DTY), Tri-Star Resources plc (TSTR.L) (TSTR) and Sirius Minerals (SXX).

Company Calendar

Last Earnings
7/20/2020
Today
11/22/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
Trading
CIK
N/A
Fax
N/A
Employees
2
Year Founded
N/A

Profitability

Net Income
£-5,070,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£783,000.00
Cash Flow
GBX 5.55 per share
Book Value
GBX 4 per share

Miscellaneous

Free Float
N/A
Market Cap
£1.93 million
Optionable
Not Optionable
Beta
0.83
20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

This page (LON:RENE) was last updated on 11/22/2024 by MarketBeat.com Staff
From Our Partners